NanoViricides Inc. Announces Imminent Animal Study for Promising Measles Drug Candidate NV-387

Reuters

06-04

<a href="https://laohu8.com/S/NNVC">NanoViricides Inc.</a> Announces Imminent Animal Study for Promising Measles Drug Candidate NV-387

NanoViricides Inc., a clinical-stage company specializing in broad-spectrum antivirals, has announced the imminent commencement of an animal study for its Measles drug development program. The study will evaluate drug candidates in a lethal animal infection model, using specially modified mice that express the human CD150/SLAM protein, necessary for Measles virus entry into cells. The company is advancing its drug NV-387, which previously demonstrated efficacy against RSV in animals and may show similar effectiveness against Measles. NV-387 acts by mimicking cell features to bind and destroy viruses. The study aims to assess NV-387's potential for treating Measles, addressing a growing need as current Measles genotypes drift from existing vaccine strains. There is currently no approved drug for Measles, with Vitamin A and ribavirin being used in specific cases. Results from this study will inform the potential human application of NV-387.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1035329) on June 04, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2540050346"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2540050346\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2540050346?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-04 18:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540050346","market":"nz","top_or_hot":-1,"title":"NanoViricides Inc. Announces Imminent Animal Study for Promising Measles Drug Candidate NV-387","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/NNVC\">NanoViricides Inc.</a> Announces Imminent Animal Study for Promising Measles Drug Candidate NV-387\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NanoViricides Inc., a clinical-stage company specializing in broad-spectrum antivirals, has announced the imminent commencement of an animal study for its Measles drug development program. The study will evaluate drug candidates in a lethal animal infection model, using specially modified mice that express the human CD150/SLAM protein, necessary for Measles virus entry into cells. The company is advancing its drug NV-387, which previously demonstrated efficacy against RSV in animals and may show similar effectiveness against Measles. NV-387 acts by mimicking cell features to bind and destroy viruses. The study aims to assess NV-387's potential for treating Measles, addressing a growing need as current Measles genotypes drift from existing vaccine strains. There is currently no approved drug for Measles, with Vitamin A and ribavirin being used in specific cases. Results from this study will inform the potential human application of NV-387.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1035329) on June 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NanoViricides Inc. Announces Imminent Animal Study for Promising Measles Drug Candidate NV-387</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNanoViricides Inc. Announces Imminent Animal Study for Promising Measles Drug Candidate NV-387\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-04 18:55</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/NNVC\">NanoViricides Inc.</a> Announces Imminent Animal Study for Promising Measles Drug Candidate NV-387\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NanoViricides Inc., a clinical-stage company specializing in broad-spectrum antivirals, has announced the imminent commencement of an animal study for its Measles drug development program. The study will evaluate drug candidates in a lethal animal infection model, using specially modified mice that express the human CD150/SLAM protein, necessary for Measles virus entry into cells. The company is advancing its drug NV-387, which previously demonstrated efficacy against RSV in animals and may show similar effectiveness against Measles. NV-387 acts by mimicking cell features to bind and destroy viruses. The study aims to assess NV-387's potential for treating Measles, addressing a growing need as current Measles genotypes drift from existing vaccine strains. There is currently no approved drug for Measles, with Vitamin A and ribavirin being used in specific cases. Results from this study will inform the potential human application of NV-387.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1035329) on June 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nNDL47VQjN:1","article_id":"2540050346","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540050346","pubTimestamp":1749034520,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"NanoViricides Inc., a clinical-stage company specializing in broad-spectrum antivirals, has announced the imminent commencement of an animal study for its Measles drug development program. The study will evaluate drug candidates in a lethal animal infection model, using specially modified mice that express the human CD150/SLAM protein, necessary for Measles virus entry into cells. The company is advancing its drug NV-387, which previously demonstrated efficacy against RSV in animals and may show similar effectiveness against Measles. NV-387 acts by mimicking cell features to bind and destroy viruses. The study aims to assess NV-387's potential for treating Measles, addressing a growing need as current Measles genotypes drift from existing vaccine strains. There is currently no approved drug for Measles, with Vitamin A and ribavirin being used in specific cases. Results from this study will inform the potential human application of NV-387.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"NanoViricides Inc.宣布即将对有前途的麻疹候选药物NV-387进行动物研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NNVC":0.9},"content_text":"NanoViricides Inc. Announces Imminent Animal Study for Promising Measles Drug Candidate NV-387\n    \n\n        NanoViricides Inc., a clinical-stage company specializing in broad-spectrum antivirals, has announced the imminent commencement of an animal study for its Measles drug development program. The study will evaluate drug candidates in a lethal animal infection model, using specially modified mice that express the human CD150/SLAM protein, necessary for Measles virus entry into cells. The company is advancing its drug NV-387, which previously demonstrated efficacy against RSV in animals and may show similar effectiveness against Measles. NV-387 acts by mimicking cell features to bind and destroy viruses. The study aims to assess NV-387's potential for treating Measles, addressing a growing need as current Measles genotypes drift from existing vaccine strains. There is currently no approved drug for Measles, with Vitamin A and ribavirin being used in specific cases. Results from this study will inform the potential human application of NV-387.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1035329) on June 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}